We have been engaged in the creation of bioactive compounds based on the multi-template approach utilizing thalidomide (1). [1] [2] [3] [4] [5] [6] The basic idea of the multi-template approach is that the number of three-dimensional spatial structures (fold structures) of human proteins is only approximately 1000, which is much smaller than the number of human proteins, estimated to be 50000-70000. [7] [8] [9] Therefore, ignoring physical/chemical interactions, a template/ scaffold structure which is spatially complementary to one fold structure might serve as a multi-template for structural development of ligands that would interact specifically with at least 50-70 different human proteins. We have focused on thalidomide (1) as a candidate multi-template structure. Thalidomide (1) was launched as a hypnotic/sedative drug in the 1950's, but was withdrawn from the market in the 1960's because of severe teratogenicity. But, subsequently, thalidomide (1) has been established to be useful for the treatment of Hansen's disease and multiple myeloma. Further, many reports have appeared on its therapeutic potential for the treatment of a range of diseases, including cancers, rheumatoid arthritis and diabetes.
We have been engaged in the creation of bioactive compounds based on the multi-template approach utilizing thalidomide (1) . [1] [2] [3] [4] [5] [6] The basic idea of the multi-template approach is that the number of three-dimensional spatial structures (fold structures) of human proteins is only approximately 1000, which is much smaller than the number of human proteins, estimated to be 50000-70000. [7] [8] [9] Therefore, ignoring physical/chemical interactions, a template/ scaffold structure which is spatially complementary to one fold structure might serve as a multi-template for structural development of ligands that would interact specifically with at least 50-70 different human proteins. We have focused on thalidomide (1) as a candidate multi-template structure. Thalidomide (1) was launched as a hypnotic/sedative drug in the 1950's, but was withdrawn from the market in the 1960's because of severe teratogenicity. But, subsequently, thalidomide (1) has been established to be useful for the treatment of Hansen's disease and multiple myeloma. Further, many reports have appeared on its therapeutic potential for the treatment of a range of diseases, including cancers, rheumatoid arthritis and diabetes. [1] [2] [3] [4] [5] [6] 10) Using our multi-template approach, we have developed many biological response modifiers, including tumor necrosis factor-a (TNF-a) production regulators, 11, 12) nitric oxide synthase (NOS) inhibitors, 13, 14) cyclooxygenase (COX) inhibitors, [15] [16] [17] liver X receptor (LXR) antagonists, [18] [19] [20] [21] a-glucosidase inhibitors [21] [22] [23] [24] and glycogen phosphorylase inhibitors. 25) On the other hand, based on a result that thalidomide inhibits the replication of human immunodeficiency virus type 1 (HIV-1), 26) we speculated that thalidomide and its derivatives might inhibit the growth of other viruses. We focused on inhibitors of the influenza virus A, and phenethylphenylphthalimide derivatives 2, 3 and 4, which were derived from thalidomide-related aglucosidase inhibitors and liver X receptors ( Fig. 1) , were found to inhibit the growth of influenza A. 27) We also investigated the mechanism of this growth inhibition and found that these compounds inhibit influenza virus PA endonuclease. So, we speculated that various inhibitors toward other DNA recognizing enzymes might be possible to generate by modification of phenethylphenylphthalimide derivatives. Thus, we screened our library of these derivatives for inhibitory activity towards restriction enzymes EcoRI, BamHI and HindIII, which resemble endonucleases and are frequently utilized in biological experiments to proof our hypothesis. EcoRI, isolated from strains of Escherichia (E.) coli, recognizes the following palindromic DNA sequence: 5Ј-GAATTC-3Ј 3Ј-CTTAAG-5Ј. BamHI, derived from Bacillus amyloliquefaciens, recognizes the palindromic sequence: 5Ј-GGATCC-3Ј 3Ј-CCTAGG-5Ј. HindIII, derived from Haemophilus influenzae, recognizes the palindromic sequence 5Ј-AAGCTT-3Ј 3Ј-TTCGAA-5Ј.
Results and Discussion
EcoRI, BamHI and HindIII were selected as target enzymes and pBR322 was selected as the assay substrate. At the initial screening of phenethylphenylphthalimide derivatives, compound 19 showed EcoRI-inhibitory activity with the IC 50 value of 70 mM (Table 1) . Compound 16 also showed weak EcoRI-inhibitory activity. Since compounds 16 and 19 possess a tetrachlorophthalimide skeletons and a dihydroxyphenyl group, these might be important for the EcoRI-inhibitory activity. Next, we tried to improve the inhibitory activity of compounds 16 and 19. Based on the results of structure-activity relationship studies, phenethylphenylphthalimides bearing trihydroxy substituents were designed as candidates for more potent EcoRI inhibitors.
These analogs were synthesized as shown in Chart 1. 3,4,5-Trimethoxybenzyl alcohol was allowed to react with PBr 3 to generate 3,4,5-trimethoxybenzyl bromide. Reaction of the intermediate with triphenylphosphine provided triphenylphosphonium salt 30. Diphenylethene derivatives 31a-c were prepared as E/Z mixtures by Wittig reaction of nitrobenzaldehyde with 30. After simultaneous reduction of the nitro group and olefin moiety of compounds 31a-c, phenethylphenylphthalimides 33a-c and 34a-c were obtained by condensation with phthalic or tetrachlorophthalic anhydride, respectively. The conversion of the methoxy groups to hydroxyl groups using BBr 3 was conducted to give trihydroxy analogs 20-22 and 24-26. Dihydroxyl analogs 23 and 27-29 were also generated in the reaction and purified by silica gel column chromatography.
Introduction of a hydroxyl group at the 5Љ position of 16 and 19, i.e., compounds 25 and 26, resulted in a drastic increase of EcoRI-inhibitory activity (Table 2) . On the other hand, the potency of analogs possessing a methoxy group instead of a hydroxyl group, i.e., compounds 28 and 29, was decreased compared with that of 25 and 26, respectively.
Hence, a hydroxyl group at the 5Љ position might be important for EcoRI-inhibitory activity. Since compounds with a hydroxyl group at the 5Љ position of the non-substituted phthalimide skeleton (20) (21) (22) had no apparent activity, the tetrachloro substitution of the phthalimide skeleton might also be important for EcoRI-inhibitory activity.
Subsequently, we evaluated the BamHI-and HindIII-inhibitory activities of the phenethylphenylphthalimide derivatives possessing EcoRI-inhibitory activity (Table 3) . Compounds 25 and 26 showed BamHI-and HindIII-inhibitory activities. Compounds 16 and 23, which possess weak EcoRIinhibitory activity, also showed weak BamHI-inhibitory ac- tivity and modest HindIII-inhibitory activity.
In conclusion, we discovered restriction enzyme inhibitors among our library of phenethylphenylphthalimide derivatives. Compounds 25 and 26 showed potent EcoRI-inhibitory activity with the IC 50 values of 4.2 and 5.3 mM, respectively, together with modest BamHI-and HindIII-inhibitory activities. These results indicate that the phenethylphenylphthalimide skeleton can be used as a multi-template for endonuclease inhibitors.
Experimental
General Melting points were determined by using a Yanagimoto hotstage melting point apparatus and are uncorrected.
1 H-NMR spectra were recorded on a JEOL JNM-GX500 (500 MHz) spectrometer. Chemical shifts are expressed in parts per million relative to tetramethylsilane. Mass spectra were recorded on a JEOL JMS-DX303 spectrometer.
General Procedure A (GP-A) To a solution of nitrobenzaldehyde in dehydrated CH 2 Cl 2 were added benzyltriphenylphosphonium salt (1.0 eq), potassium carbonate (1.1 eq) and 18-crown-6 (0.18 eq) and the mixture was refluxed, then filtered and concentrated. The residue was purified by silica gel column chromatography to give the target compound as an E/Z mixture.
General Procedure B (GP-B) Substituted nitrobenzene was dissolved in EtOAc and hydrogenated with 10% Pd/C (catalytic amount). The mixture was filtered through a pad of Celite, and the filtrate was evaporated under reduced pressure. The residue was purified by silica gel columnn chromatography to give the target compound.
General Procedure C (GP-C) A mixture of phthalic anhydride and substituted aniline (1.0 eq) was heated at 160 or 200°C for 1 h. After the reaction was completed, the residue was purified by silica gel column chromatography to give the target compound.
General Procedure D (GP-D) To a solution of substituted methoxybenzene in dehydrated dichloromethane was added dropwise boron tribromide (1.0 M solution in dichloromethane) (10 eq) at 0°C under an argon atmosphere. The mixture was stirred for 5-60 min, then poured into water and extracted with CH 2 Cl 2 . The organic layer was washed with H 2 O and dried over MgSO 4 . The solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography to give the target compound.
Triphenyl-(3,4,5-trimethoxybenzyl)phosphonium Bromide (30) To a solution of 3,4,5-trimethoxybenzyl alcohol (1.98 g, 10 mmol) in dichloromethane (15 ml) was added dropwise phosphorus tribromide (658 ml, 7 mmol) at 0°C under an argon atmosphere. The mixture was stirred for 1 h, then poured into ice water (50 ml) and alkalized with sat. NaHCO 3 (50 ml). The aqueous mixture was extracted with CH 2 Cl 2 (20 mlϫ 3). The organic layer was washed with H 2 O (20 mlϫ2) and then dried over 4,5,6,7-Tetrachloro-2-{3-[2-(3,4,5-trihydroxyphenyl) ethyl]phenyl}-isoindole-1,3-dione (25) and 4,5,6,7-Tetrachloro-2-{3-[2-(3,4-dihydroxy-5-methoxyphenyl)ethyl]phenyl}isoindole-1,3-dione (28) These compounds were prepared from 34b by means of GP-D. Compounds 25 and 28 was obtained in 13% yield as colorless needles after recrystallization from EtOAc/n-hexane and in 10% yield as yellow needles after recrystallization from EtOAc/n-hexane, respectively.
25: mp 249.0-250.5°C.
